Health Populi
AUGUST 22, 2022
And that data will be generated from many sources, frequently siloed and decentralized which can prevent aggregation, mash-up, and analysis. The Swiss Re table calls out five stakeholder groups, one of which was not called out in the McKinsey analysis: collaborating with consumers/patients.
Health Populi
APRIL 1, 2022
This graphic illustrates that about one-half of companies listed on the S&P have a direct impact on people’s health: think pharma, life sciences, medical technology, health insurance, food, and transportation. The bar chart illustrates the result of the meta-analysis which considered 148 studies on mortality and risk factors.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
MAY 23, 2023
This study shows the ability of digital solutions to offer a win-win for patients and providers – the opportunity to spot cognitive impairment sooner and do so using technology that makes assessments more efficient and actionable for regular use in clinical practice, especially primary care.”
Health Populi
MAY 30, 2023
Some consumers will consider them a tech and e-commerce player primarily; others in terms of a pharmacy or primary care provider; and still others might consider Whole Foods part of their retail grocery channel, competing with Kroger, Aldi, and the “excellent” Trader Joe’s.
Health Populi
JUNE 1, 2023
Some consumers will consider them a tech and e-commerce player primarily; others in terms of a pharmacy or primary care provider; and still others might consider Whole Foods part of their retail grocery channel, competing with Kroger, Aldi, and the “excellent” Trader Joe’s.
Health Populi
MAY 29, 2023
Some consumers will consider them a tech and e-commerce player primarily; others in terms of a pharmacy or primary care provider; and still others might consider Whole Foods part of their retail grocery channel, competing with Kroger, Aldi, and the “excellent” Trader Joe’s.
Health Populi
JUNE 30, 2023
Here is a de ep analysis from GoodRx on the launch of at least 9 Humira biosimilars for 2023, foretelling this one product alone could have a major impact on the overall cost of prescription drugs in the U.S. In 2023, the Humira biosimilar launch is seen as a “new milestone” for biosimilars in the U.S. for 2024 medical trend.
Expert insights. Personalized for you.
293 
Let's personalize your content